0 6 Single single JJ 7 12 point point NN 13 23 estimation estimation NN 24 26 of of IN 27 41 glucocorticoid glucocorticoid NN 42 51 receptors receptor NNS 52 54 in in IN 55 66 lymphocytes lymphocyte NNS 67 69 of of IN 70 76 normal normal JJ 77 85 subjects subject NNS 86 89 and and CC 90 92 of of IN 93 101 children child NNS 102 107 under under IN 108 112 long long JJ 113 117 term term NN 118 132 glucocorticoid glucocorticoid NN 133 142 treatment treatment NN 142 143 . . . 145 146 A a DT 147 153 single single JJ 154 159 point point NN 160 165 assay assay NN 166 168 of of IN 169 183 glucocorticoid glucocorticoid NN 184 193 receptors receptor NNS 194 195 ( ( ( 195 197 GR GR NNP 197 198 ) ) ) 199 201 in in IN 202 207 human human JJ 208 219 lymphocytes lymphocyte NNS 220 225 based base VBN 226 228 on on IN 229 232 the the DT 233 244 measurement measurement NN 245 247 of of IN 248 256 specific specific JJ 257 270 dexamethasone dexamethasone NN 271 278 binding binding NN 279 282 has have VBZ 283 287 been be VBN 288 297 developed develop VBN 298 301 and and CC 302 310 compared compare VBN 311 315 with with IN 316 317 a a DT 318 324 common common JJ 325 336 multi-point multi-point JJ 337 346 Scatchard Scatchard NNP 347 355 analysis analysis NN 355 356 . . . 357 360 The the DT 361 366 assay assay NN 367 391 conditions-concentration conditions-concentration NN 392 394 of of IN 395 398 the the DT 399 405 ligand ligand NN 406 408 20 20 CD 409 415 nmol/l nmol/l NN 415 416 , , , 417 427 incubation incubation NN 428 432 time time NN 433 434 2 2 CD 435 436 h h NN 437 440 and and CC 441 444 the the DT 445 449 cell cell NN 450 455 count count NN 456 459 2-6 2-6 CD 460 464 mil. mil. CD 465 475 cells/tube cells/tube NNS 476 478 in in IN 479 482 the the DT 483 488 assay assay NN 489 495 volume volume NN 496 500 0.25 0.25 CD 501 503 ml ml NN 504 508 were be VBD 509 514 found find VBN 515 517 to to TO 518 520 be be VB 521 528 optimal optimal JJ 528 529 . . . 530 532 An an DT 533 540 attempt attempt NN 541 544 was be VBD 545 549 also also RB 550 560 undertaken undertake VBN 561 563 to to TO 564 567 use use VB 568 569 a a DT 570 574 cell cell NN 575 584 harvester harvester NN 585 588 for for IN 589 592 the the DT 593 603 separation separation NN 604 606 of of IN 607 612 cells cell NNS 613 617 from from IN 618 625 unbound unbound JJ 626 632 ligand ligand NN 632 633 . . . 634 640 Though though IN 641 653 specifically specifically RB 654 659 bound bind VBN 660 673 dexamethasone dexamethasone NN 674 682 measured measure VBN 683 685 by by IN 686 696 whole-cell whole-cell JJ 697 702 assay assay NN 703 706 and and CC 707 711 that that IN 712 717 using use VBG 718 722 cell cell NN 723 732 harvester harvester NN 733 743 correlated correlate VBD 744 748 well well RB 748 749 , , , 750 756 almost almost RB 757 759 by by IN 760 763 one one CD 764 769 order order NN 770 775 lower low JJR 776 782 values value NNS 783 791 obtained obtain VBN 792 796 with with IN 797 800 the the DT 801 807 latter latter JJ 808 814 method method NN 815 821 render render VBP 822 824 it it PRP 825 839 non-applicable non-applicable JJ 840 843 for for IN 844 852 receptor receptor NN 853 865 quantitation quantitation NN 865 866 . . . 867 870 The the DT 871 878 results result NNS 879 883 from from IN 884 885 9 9 CD 886 893 healthy healthy JJ 894 904 volunteers volunteer NNS 905 906 ( ( ( 906 913 average average JJ 914 916 GR gr NN 917 930 concentration concentration NN 931 935 7131 7131 CD 936 939 +/- +/- CC 940 944 1256 1256 CD 945 955 sites/cell sites/cell NNS 955 956 ) ) ) 957 967 correlated correlate VBD 968 979 excellently excellently RB 980 984 with with IN 985 990 those those DT 991 999 obtained obtain VBN 1000 1002 by by IN 1003 1006 the the DT 1007 1016 Scatchard Scatchard NNP 1017 1025 analysis analysis NN 1025 1026 . . . 1027 1030 The the DT 1031 1037 single single JJ 1038 1043 point point NN 1044 1049 assay assay NN 1050 1053 has have VBZ 1054 1058 been be VBN 1059 1063 also also RB 1064 1071 applied apply VBN 1072 1075 for for IN 1076 1089 determination determination NN 1090 1092 of of IN 1093 1095 GH GH NNP 1096 1098 in in IN 1099 1101 10 10 CD 1102 1110 children child NNS 1111 1118 treated treat VBN 1119 1123 with with IN 1124 1129 large large JJ 1130 1135 doses dose NNS 1136 1138 of of IN 1139 1149 prednisone prednisone NN 1149 1150 . . . 1151 1154 The the DT 1155 1162 average average JJ 1163 1169 values value NNS 1170 1174 from from IN 1175 1182 healthy healthy JJ 1183 1193 volunteers volunteer NNS 1194 1197 did do VBD 1198 1201 not not RB 1202 1208 differ differ VB 1209 1222 significantly significantly RB 1223 1227 from from IN 1228 1233 those those DT 1234 1239 found find VBN 1240 1242 in in IN 1243 1248 these these DT 1249 1257 children child NNS 1257 1258 , , , 1259 1265 though though RB 1266 1270 much much RB 1271 1278 broader broad JJR 1279 1284 range range NN 1285 1288 was be VBD 1289 1294 found find VBN 1295 1297 in in IN 1298 1306 patients patient NNS 1306 1307 . . .